The transformative potential of research, innovation and Artificial Intelligence in improving the lives of people living with thalassaemia and other haemoglobinopathies was at the centre of a high-level visit by the Chief Scientist for Research, Innovation and Technology of the Republic of Cyprus, Demetris Skourides, to the Thalassaemia International Federation (TIF).
As noted in a press release from the office of the Chief Scientist, during the visit, Skourides was welcomed by the leadership team of the Thalassaemia International Federation and received a comprehensive briefing from the Federation’s Executive Director, Dr. Androulla Eleftheriou, on the organisation’s global mission, strategic priorities and international impact.
Dr. Eleftheriou presented TIF’s leading role in providing guidance, promoting best practices, supporting research, advising policymakers and strengthening the voice of patients across health systems worldwide. She also presented recent developments relating to the work being advanced by the Federation and key stakeholders in support of the National Strategy for Blood, underlining the importance of coordinated policy, patient-centred planning, prevention, quality care and equitable access to safe and effective blood services.
For decades, the Thalassaemia International Federation has served as a global reference point for the thalassaemia community. Its work brings together patients, families, clinicians, researchers, governments, public authorities and international organisations around a common purpose: improving care, advancing knowledge and enhancing quality of life for every person affected by thalassaemia and other haemoglobinopathies.
A key focus of the discussions was the role of digital innovation, chatbot technologies and responsible Artificial Intelligence in expanding TIF’s global reach and impact. These technologies present significant opportunities to provide real-time, accessible support to patients and families, facilitate access to trusted information, and help healthcare professionals remain informed about emerging therapies, clinical trials, scientific developments and international treatment guidelines.
Commenting on the importance of access to knowledge, Dr. Androulla Eleftheriou stated, “For the thalassaemia community, access to knowledge is access to life. Through guidance, research, policy advisory and digital innovation, including chatbot tools, TIF works every day to ensure that no patient is left behind, providing real-time, accessible services to communities around the world.”
The meeting reinforced a shared principle that technology must ultimately serve people. While Artificial Intelligence can empower patients, support clinicians, strengthen health systems and accelerate access to knowledge, it must always be implemented responsibly and in a manner that respects human judgement, medical expertise and person-centred care.
Reflecting on the discussions, Demetris Skourides noted, “The work of the Thalassaemia International Federation demonstrates what human-centred innovation is truly about: harnessing science, technology and collaboration to improve lives.”
Skourides added, “Artificial Intelligence provides us with powerful new tools to expand access to knowledge, support healthcare professionals, reduce barriers for patients and accelerate better health outcomes. However, its purpose must always remain clear: to serve people. Through responsible innovation and strong partnerships, we can build healthcare systems that are more inclusive, more informed and better prepared for the future.”
A central theme of the visit was the importance of equality in healthcare. Access to accurate information, specialised care, safe blood services, new therapeutic developments and clinical expertise should not depend on geography, language, income or the capacity of a national health system. By combining TIF’s global leadership with AI-enabled tools, digital education, research collaboration and policy advisory services, new pathways can be created towards more inclusive, accessible and personalised healthcare.
The visit also highlighted Cyprus’s unique position within the global thalassaemia ecosystem. As the home of the Thalassaemia International Federation and a country with extensive experience in thalassaemia prevention, patient care, public health coordination and blood-policy development, Cyprus is uniquely positioned to play an even greater international leadership role in responsible health innovation.
By connecting TIF’s international mission with Cyprus’s broader agenda in research, innovation, Artificial Intelligence and health policy, Cyprus has the opportunity to further establish itself as a global meeting point for thalassaemia expertise, patient advocacy, digital health, research collaboration, blood-policy coordination and healthcare innovation.
The Thalassaemia International Federation reaffirmed its commitment to advancing science, education, guidance, policy advisory and strategic partnerships that improve quality of life for people living with thalassaemia and other haemoglobinopathies worldwide.
The visit concluded with a shared commitment to deepen cooperation and explore practical opportunities through which research, innovation and Artificial Intelligence can support patients, empower healthcare professionals, inform policymakers, strengthen blood-system readiness and contribute to advancing global health equity, the press release concluded.
